We were pleased to welcome Andre Hoekema, Sr. VP Corporate Development at Galapagos, at a time when all eyes are turned on filgotinib, the company’s late stage pipeline asset which is expected to be partnered by year-end. Andre seems confident in the company’s ability to close a deal in the upcoming weeks with metrics better or as good as the ones from the ABBV deal. We do not rule out that the company has term sheets in hand. The Cystic Fibrosis programme is on track with several compounds expected to reach the clinic within the next 6 to 12 months.
For more information, please contact email@example.com